I had not realized that they had changed the phase 3 ipi administration to week 1,4,7,10.
By my reading it is now week 2,5,8,11 as it has been in prior studies including phase 1/2.
My suspicion is that they are seeing it takes a little more time for Tilso to prime the immune microenvironment so starting at week 2 (as before) is a better fit. It is something they are likely seeing on the translational data. I hope this is just tweaking the protocol rather than less impressive findings the way it was set up for phase 3. I guess it could always be some logistic reason as well.